Cognitive Screening in Lung Cancer Patients

Cognitive Screening in Lung Cancer Patients

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Inclusion Criteria:

• Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
• Age ≥ 18 years
• Patients able to speak and read the local language(s) fluently
• Acceptance and signature of informed consent

Exclusion Criteria:

• Age ≥ 70
• Presence of brain metastases
• Patients with concomitant neurological or psychiatric disorders.
• Patients undergoing brain radiotherapy
• Previous diagnosis of lung cancer